Pascal Goldschmidt

Pascal J. Goldschmidt-Clermont, M.D., is a Belgian-born, American cardiologist, and is the Senior Vice President for Medical Affairs and the Dean of the Miller School of Medicine at the University of Miami. He was previously the Edward S. Orgain Professor of Cardiology and Chairman of the Department of Medicine at Duke University Medical Center. He received his medical degree from the Universite Libre de Bruxelles, and completed residency and fellowship training in Brussels at Erasme Academic Hospital and in the United States at Johns Hopkins University.

Sources

[http://www6.miami.edu/UMH/CDA/UMH_Main/1,1770,2472-1;46713-3,00.html Pascal Goldschmidt biography ] at the University of Miami

Publications

1. Désir D, Féry F, Goldschmidt-Clermont P, Goldschmidt D, Van Gansbeke D, Verhoeven A. [Clinical applications of an extracorporeal pancreas] [Article in French] Brux Med. 1979 Nov-Dec;59(11-12):497-502.

2. Graff GL, Gueuning C, Glupczynski Y, Goldschmidt P. Systemic effects of colchicine on phosphate metabolism in innervated and denervated, slow and fast muscles of the rat. Arch Internat Physiol Biochim 88:393-405, 1980.

3. Goldschmidt P, Glupczynski Y, Gueuning C, Graff GL. Systemic effects of podophyllotoxin on phosphate metabolism in innervated and denervated, slow and fast muscles of the rat. Arch Internat Physiol Biochim 88:465-74, 1980.

4. Nel AE, Landreth GE, Goldschmidt-Clermont PJ, Tung HE, Galbraith RM. Enhanced tyrosine phosphorylation in B lymphocytes upon complexing of membrane immunoglobulin. Biochem Biophys Res Comm 125:859-866, 1984.

5. Goldschmidt-Clermont P, Petrini M, Khansari N, Fudenberg HH. The role of PNP enzyme in autologous rosette-forming cells. Cell Immunol 87(2): 340-347, 1984.

6. Khansari N, Petrini M, Ambrogi F, Goldschmidt-Clermont P, Fudenberg HH. Role of autorosette forming cells in antibody synthesis in vitro: suppressive activity of ARFC in humoral immune response. Immunobiology 166(1): 1-11, 1984.

7. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Nel AE, Werner PM. Effect of ligand binding upon measurement of Gc by rocket immunoelectrophoresis: implications for protein determination and for studies of protein/ligand interaction. Electrophoresis 6:155-161, 1985.

8. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Werner PM, Nel AM, Lee WM. Accurate quantitation of native Gc in serum and estimation of endogenous Gc:G-actin complexes by rocket immunoelectrophoresis. Clin Chim Acta, 148:173-183, 1985.

9. Lee WM, Emerson DL, Werner PM, Arnaud P, Goldschmidt-Clermont P, Galbraith RM. Decreased serum group specific component protein levels and complexes with actin in fulminant hepatic necrosis. Hepatology 5:271-275, 1985.

10. Nel AE, Navailles M, Emerson DL, Goldschmidt-Clermont P, Pathak SK, Tsang KY, Galbraith RM. Altered configuration of Gc on the plasma membrane of transformed and malignant human B lymphocytes. Clin Immunol Immunopathol 37:191-202, 1985.

11. Nel AE, Wooten MW, Goldschmidt-Clermont PJ, Miller PJ, Stevenson HC, Galbraith RM. Polymyxin B causes coordinate inhibition of phorbol ester-induced C-Kinase activity and proliferation of B lymphocytes. Biochem Biophys Res Comm 128:1364-1372, 1985.

12. Nel AE, Navailles M, Rosberger DF, Landreth GE, Goldschmidt-Clermont PJ, Baldwin GJ, Galbraith RM. Phorbol ester induces tyrosine phosphorylation in normal and abnormal human B lymphocytes. J Immunol 135:3448-345, 1985.

13. Wooten MW, Nel AE, Goldschmidt-Clermont PJ, Galbraith RM, Wrenn RW. Identification of a major endogenous substrate for phospholipid/Ca2+-dependent kinase in pancreatic acini as Gc (Vitamin D-binding protein). FEBS Lett 191:97-101, 1985.

14. Goldschmidt-Clermont PJ, Galbraith RM, Emerson DL, Marsot F, Nel AE, Arnaud P. Distinct sites on the G-actin molecule bind group-specific component and deoxyribonuclease I. Biochem J 228:471-477, 1985.

15. Nel AE, Wooten MW, Landreth GE, Goldschmidt-Clermont PJ, Stevenson HC, Miller PJ, Galbraith RM. Translocation of phospholipid/Ca2+-dependent protein kinase in B lymphocytes activated by phorbol ester or crosslinking of membranes immunoglobulin. Biochem J 233:145-149, 1986.

16. Goldschmidt-Clermont PJ, Allen PC, Nel AE, Emerson DL, Day JR, Galbraith RM. Gc (Vitamin D-binding protein) binds the 33.5 K tryptic fragment of actin. Life Sci 38:735-742, 1986.

17. Miribel L, Goldschmidt-Clermont P, Galbraith RM, Arnaud P. Rapid purification of native group-specific component (Vitamin D-binding protein) by differential affinity for immobilized triazine dyes. J Chromatogr 363:448-455, 1986.

18. Goldschmidt-Clermont PJ, Van Alstyne EL, Day JR, Nel AE, Emerson DL, Lazarchick J, Galbraith RM. Group-specific component (vitamin D-binding protein) prevents the interaction between G-actin and profilin. Biochemistry 25:6467-6472, 1986.

19. Krayer JW, Emerson DL, Goldschmidt-Clermont PJ, Nel AE, Werner PA, Galbraith RM. Qualitative and quantitative studies of Gc (Vitamin D-binding protein) in saliva from normals and patients with periodontal disease. J Periodont Res 22:259-263, 1987.

20. Katikaneni LP, Emerson DL, Goldschmidt-Clermont PJ, Loadholt BL, Levkoff AH, Galbraith RM. High levels of group specific component (vitamin D-binding protein) in the cerebrospinal fluid of infant aged less than two months. Biol Neonate 52:250-255, 1987.

21. Young WO, Goldschmidt-Clermont PJ, Lee WM, Emerson DL, Jollow DJ, Galbraith RM. Correlation between extent of liver damage in fulminant hepatic necrosis and complexing of circulating Gc (vitamin D-binding protein). J Lab Clin Med 110:83-90, 1987.

22. Lee WM, Emerson DL, Young WO, Goldschmidt-Clermont PJ, Jollow DJ, Galbraith RM. Diminished serum Gc (vitaminD-binding protein)levels and increased Gc:G-actin complexes in a hamster model of fulminant hepatic necrosis (FHN). Hepatology 7:825-830, 1987.

23. Goldschmidt-Clermont PJ, Williams MH, Galbraith RM. Altered conformation of Gc (vitamin D-binding protein) upon complexing with cellular actin. Biochem Biophys Res Comm 146:611-617, 1987.

24. Goldschmidt-Clermont PJ, Lee WM, Galbraith RM. Proportion of circulating Gc (vitamin D-binding protein) in complexed form: relation to clinical outcome in fulminant hepatic necrosis. Gastroenterology 94:1454-1458, 1988.

25. Goldschmidt-Clermont PJ, Van Baelen H, Bouillon R, Shook TE, Williams MH, Nel AE, Galbraith RM. Role of group specific component (vitamin D-binding protein) in clearance of actin from the circulation in the rabbit. J Clin Invest 81:1519-1527, 1988.

26. Kaiser DA, Goldschmidt-Clermont PJ, Levine BA, Pollard TD. Characterization of renatured profilin purified by urea elution from poly-l-proline agarose columns. Cell Motility and Cytoskeleton 14:251-262, 1989.

27. Goldschmidt-Clermont PJ, Machesky LM, Baldassare JJ, Pollard TD. The actin-binding protein profilin binds to PIP2 and inhibits its hydrolysis by phospholipase-C. Science 247:1575-1578, 1990.

28. Machesky LM, Goldschmidt-Clermont PJ, Pollard TD. The affinities of human platelet and Acanthamoeba profilin isoforms for polyphosphoinositides account for their relative abilities to inhibit phospholipase C. Cell Regulation 1:937-950, 1990.

29. Goldschmidt-Clermont PJ, Kim JW, Machesky LM, Rhee SG, Pollard TD. Regulation of phospholipase  by profilin and tyrosine phosphorylation. Science 251:1231-1233, 1991.

30. Goldschmidt-Clermont PJ, Machesky LM, Doberstein SK, Pollard TD. Mechanism of the interaction of human platelet profilin with actin. J Cell Biol 113:1081-1089, 1991.

31. Goldschmidt-Clermont PJ and Janmey PA. Profilin: a weak CAP for actin and RAS. Cell 66:419-421, 1991.

32. Goldschmidt-Clermont PJ, Furman MI, Wachsstock D, Safer D, Nachmias VT, Pollard TD. The control of actin nucleotide exchange by thymosinb4 and profilin. A potential regulatory mechanism for actin polymerization in cells. Mol Biol Cell 3:1015-1024, 1992.

33. Goldschmidt-Clermont PJ, Mendelsohn ME, Gibbs JB. Rac and Rho in control. Current Biol 2:669-671, 1992.

34. Furman MI, Gardner TM, Goldschmidt-Clermont PJ. Mechanism of cytoskeletal reorganization during platelet activation. Thromb Haemostas 70:229-232, 1993.

35. Heldman AW, Goldschmidt-Clermont PJ. Cell signalling and motile activity. Symp Soc Exp Biol. 1993;47:317-24.

36. Finkel T, Theriot JA, Dise KR, Tomaselli GF, Goldschmidt-Clermont PJ. Dynamic actin structures stabilized by profilin. Proc Natl Acad USA 91:1510-1514, 1994.

37. Theriot JA, Rosenblatt J, Portnoy DA, Goldschmidt-Clermont PJ, Mitchison TJ. Involvement of profilin in the actin-based motility of L. monocytogenes in cells and cell-free extracts. Cell 76:505-517, 1994.

38. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence activated flow cytometry. J Lab Clin Med 123:728-740, 1994.

39. Gips SJ, Kandzari DE, Goldschmidt-Clermont PJ. Growth factor receptors, phospholipases, phospholipid kinases and actin reorganization. Sem Cell Biol 5:201-208, 1994.

40. Sohn RH, and Goldschmidt-Clermont PJ. Profilin: at the crossroads of signal transduction and the actin cytoskeleton. Bio Essays 16:465-472, 1994.

41. Furman MI, Grigoryev D, Bray PF, Dise KR, Goldschmidt-Clermont PJ. Platelet tyrosine kinase and fibrinogen receptor activation. Circ Res 75:172-180, 1994.

42. Kamp TJ, Goldschmidt-Clermont PJ, Brinker JA, Resar JR. Myocardial infarction, aortic dissection, and thrombolytic therapy. Am Heart J 128:1234-1237, 1994.

43. Rosenfeld BA, Faraday N, Campbell D, Dise K, Bell W, Goldschmidt P. Hemostatic effects of stress hormone infusion. Anesthesiology 81:1116-1126, 1994.

44. Addo JB, Bray PF, Faraday N, Grigoryev D, Goldschmidt-Clermont PJ. Surface recruitment but not activation of integrin Iib3 (GPIIb-IIIa) requires a functional actin cytoskeleton. Arteriosc Thromb Vascul Biol 15:1466-1473, 1995.

45. Sohn RH, Chen J, Koblan KS, Bray PF, Goldschmidt-Clermont PJ. Localization of a Binding Site for Phosphatidylinositol 4,5-Bisphosphate on Human Profilin. J Biol Chem 270:21114-21120, 1995.

46. Weiss EJ, Goldschmidt-Clermont PJ, Grigoryev D, Jin Y, Kickler TS, Bray PF. A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes P1A1 from P1A2. Tissue Antigens 46:374-381, 1995.

47. Heldman AW, Tucker RW, Crawford LE, Kandzari DE, Fearon ER, Koblan KS, Goldschmidt-Clermont PJ. EJ-Ras inhibits Phospholipase C1, but not actin polymerization induced by platelet-derived growth factor (PDGF)-BB via phosphatidylinositol-3 kinase. Circ Res 78:312-321, 1996.

48. Melillo G, Lima JAC, Judd RM, Goldschmidt-Clermont PJ, Silverman HS. Intrinsic myocyte dysfunction and tyrosine kinase pathway activation underlie the impaired wall thickening of adjacent regions during post-infarct left ventricular remodeling. Circulation 93: 1447-1458, 1996.

49. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. New Engl J Med 334:1090-1094, 1996.

50. Goldschmidt-Clermont PJ, Shear WS, Swartzberg J, Varga CF, Bray PF. Clues to the death of an Olympic champion. Lancet 347: 1833, 1996.

51. Schulman SP, Goldschmidt-Clermont PJ, Topol, EJ. The effects of Integrelin, a platelet glycoprotein Iib-IIIa receptor antagonist, in unstable angina: a randomized multicenter placebo-controlled trial. Circulation 94: 2083-2089, 1996.

52. Crawford LE, Milliken EE, Zweier JL, Becker L, Johnson T, Eissa NT, Crystal RG, Goldschmidt-Clermont PJ. Superoxide-mediated Actin Response in Post-Hypoxic Endothelial Cells. J Biol Chem 271: 26863-26867, 1996.

53. Goldschmidt-Clermont PJ, Schulman SP, Bray PF, Chandra NC, Grigoryev D, Dise KR, Sagar M, Fox RJ, Coleman LD, Richardson C, Dorsey F, du Mee C, Kitt MM, Baughman KL, Gerstenblith G. Refining the treatment of women with unstable angina—a randomized, double blind, comparative safety and efficacy of Integrelin versus aspirin in the management of unstable angina. Clin Cardiol 19: 869-874, 1996.

54. Sundaresan M, Yu Z-X, Ferrans VJ, Sulciner DJ, Gutkind JS, Irani K, Goldschmidt-Clermont PJ, Finkel T. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J 318: 379-382, 1996.

55. Sulciner DJ, Irani K, Yu Z-X, Ferrans VJ, Goldschmidt-Clermont P, Finkel T. Rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-KappaB activation. Molec Cell Biol 16: 7115-7121, 1996.

56. Schecter AD, Goldschmidt-Clermont PJ, McKee G, et al. Influence of gender, race, and education on patient preferences and receipt of cardiac catheterization among coronary care unit patients. Am J Cardiol, 78: 996-1001, 1996.

57. Fleischer KJ, Goldschmidt-Clermont PJ, Fonger JD, Hutchins GM, Baumgartner WA. One-month histologic response of transmyocardial laser channels with molecular intervention. Ann Thorac Surg 62: 1051-1058, 1996.

58. Moldovan NI, Milliken EE, Irani K, Chen J, Sohn RH, Finkel T, Goldschmidt-Clermont PJ. Regulation of endothelial cell adhesion by profilin. Curr Biol 7:24-30, 1997.

59. Irani K, Xia Y, Zweier JL, Sollott S, Der C, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275:1649-1652, 1997.

60. Faraday N, and Goldschmidt-Clermont PJ. Gender Differences in Platelet GPIIb-IIIa Activation. Thromb Haemostas 77(4):748-754, 1997.

61. Alvarez RJ, Gips SJ, Moldovan N, Wilhide CC, Milliken EE, Hoang AT, Hruban RH, Silverman HS, Dang CV, Goldschmidt-Clermont PJ. 17beta-estradiol inhibits apoptosis of endothelial cells. Biochem Biophys Res Comm 237:372-381, 1997.

62. Motevalli M, Goldschmidt-Clermont PJ, Virgil D, Kwiterovich PO. Abnormal protein tyrosine phosphorylation in fibroblasts from hyperapobetalipoprotein subjects. J Biol Chem 272:24703-24709, 1997.

63. Bray PF, Weiss EJ, Tayback M, Goldschmidt-Clermont PJ. PLA1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease. Lancet 349:1100-1101, 1997.

64. Takahashi A, Goldschmidt-Clermont PJ, Alnemri ES, Fernandes-Alnemri T, Yoshizawa-Kumagaya K, Nakajima K, Sasada M, Poirier GG, Earnshaw WC. Inhibition of ICE-related proteases (caspases) and nuclear apoptosis by phenylarsine oxide. Exp Cell Res 231:123-131, 1997.

65. Jones SA, Goldschmidt-Clermont PJ, Grigoryev D, Aversano T. Effect of stenosis shape on thrombus formation in an in vitro blood flow model. American Society of Mechanical Engineers, Bioenegineering Division BED, 35, 279-280.

66. Moore KA, Sethi R, Doanes AM, Johnson TM, Pracyk JB, Kirby M, Irani K, Goldschmidt-Clermont PJ, Finkel T. Rac1 is required for cell proliferation and G2/M progression. Biochem J 326:17-20, 1997.

67. Irani K and Goldschmidt-Clermont PJ. Ras, Superoxide and Signal Transduction. Biochem Pharm 55(9):1339-1346, 1998.

68. Cooke GE, Bray PF, Hamlington J, Pham Y, Goldschmidt-Clermont PJ. PlA2 polymorphism and efficacy of aspirin. Lancet 351:1253, 1998.

69. Kim K-S, Takeda K, Sethi R, Pracyk JB, Tanaka K, Zhou YF, Yu Z-X, Ferrans VJ, Bruder JT, Kovesdi I, Irani K, Goldschmidt-Clermont P, Finkel T: Protection from Reoxygenation Injury by Inhibition of rac1. J Clin Invest 101(9):1821-1826, 1998.

70. Wagner KR; Giles WH; Johnson CJ; Ou CY; Bray PF; Goldschmidt-Clermont PJ; Croft JB; Brown VK; Stern BJ; Feeser BR; Buchholz DW; Earley CJ; Macko RF; McCarter RJ; Sloan MA; Stolley PD; Wityk RJ; Wozniak MA; Price TR; Kittner SJ. Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: The Stroke Prevention in Young Women Study. Stroke 29:581-585, 1998.

71. Kelly SA; Goldschmidt-Clermont PJ; Milliken EE; Arai T; Smith EH; Bulkley GB. Protein tyrosine phosphorylation mediates TNF-induced endothelial-neutrophil adhesion in vitro. Am J Physiol 274:H513-519, 1998.

72. Markovitz JH, Kulkami K, Goldschmidt-Clermont P, Kiefe CL, Rustagi P, Sekar P, Nanda N: Increased platelet activation and fibrinogen in Asian Indians: Potential implications for coronary risk. Eur Heart J 19:720-726, 1998.

73. Arai T, Kelly SA, Brengman ML, Takano M, Smith EH, Goldschmidt-Clermont PJ, Bulkley GB. Ambient but not incremental oxidant generation effects intracellular adhesion molecule 1 induction by tumour necrosis factor in endothelium. Biochem J 331:853-861, 1998.

74. Irani K, Pham Y, Coleman LD, Roos C, Cooke GE, Miodovnik A, Karim N, Wilhide CC, Bray PF, Goldschmidt-Clermont PJ. Priming of Platelet Iib3 by Oxidants is Associated with Tyrosine Phosphorylation of 3. Arterioscl Thrombo Vasc Biol 18:1698-1706, 1998.

75. Moldovan NI, Qian Z, Chen Y, Dong C, Ying A, Hruban RH, Flavahan NA, Baldwin III WM, Sanfilippo F, Goldschmidt-Clermont PJ. Fas-mediated apoptosis in accelerated graft arteriosclerosis. Angiogenesis 2(3):245-254, 1998.

76. Pracyk JB, Tanaka K, Hegland DD, Kim KS, Sethi R, Rovira II, Blazina DR, Lee L, Bruder JT, Kovesdi I, Goldschmidt-Clermont PJ, Irani K, Finkel T. A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J Clin Invest 102:929-37, 1998.

77. Doanes AM, Irani K, Goldschmidt-Clermont PJ, Finkel T. A requirement for rac1 in the PDGF-stimulated migration of fibroblasts and vascular smooth cells. Biochem Mol Biol Int 45(2): 279-287, 1998.

78. Goldschmidt-Clermont PJ, and Moldovan L. Stress, superoxide and signal transduction. Gene Expr 7: 255-260, 1999.

79. Goldschmidt-Clermont PJ, Roos C, Cooke GE. P1A2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics. J Thrombosis and Thrombolysis 8(2): 89-103, 1999.

80. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, Heldman A, Sussman MS, Ouyang P, Milliken EE, Issa PJP. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 43(4):985-991, 1999.

81. Arai M, Masui Y, Goldschmidt-Clermont P, DiPaula A, Siu C, Kondo T, Becker LC. P-selectin inhibition prevents early neutrophil activation but provides only modest protection against myocardial injury in dogs with ischemia and 48 hours reperfusion. J Am Coll Cardiol 34(1): 280-8, 1999.

82. Moldovan L, Irani K, Moldovan, NI, Finkel T, Goldschmidt-Clermont PJ. The actin cytoskeleton reorganization induced by rac1 requires the production of superoxide. Antioxidants and Redox Signaling 1(1): 29-43, 1999.

83. Yeh LH, Park YJ, Hansalia RJ, Ahmed IS, Deshpande SS, Goldschmidt-Clermont PJ, Irani K, Alevriadou BR. Shear-induced tyrosine phosphorylation in endothelial cells requires Rac1-dependent production of ROS. Am J Physiol 276(4Pt1): C838-C847, 1999.

84. Goldschmidt-Clermont PJ, Coleman LD, Pham YM, Cooke GE, Shear WS, Weiss EJ, Kral BG, Moy TF, Yook RM, Blumenthal RS, Becker DM, Becker L, Bray PF. Higher prevalence of GPIIIa PlA2 polymorphism in siblings of patients with premature coronary heart disease. Arch Path Lab Med 123(12): 1223-1229, 1999.

85. Kandzari DE, Goldschmidt-Clermont PJ. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 281(5): 415, 1999.

86. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GP IIIa PIA polymorphisms display different sensitivities to agonists. Circulation 101:1013-1018, 2000.

87. Ying AK, Hassanain HH, Roos CM, Smiraglia DJ, Issa JPJ, Michler RE, Caligiuri M, Plass, Goldschmidt-Clermont PJ. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. Cardiovasc Res 46(1): 172-179, 2000.

88. Dong C, Li Z, Alvarez R, Feng ZH, Goldschmidt-Clermont PJ. Microtubule binding to Smads may regulate TGF activity. Mol Cell 6(1): 27-34, 2000.

89. Qiu P, Moeschberger ML, Cooke GE, Goldschmidt-Clermont PJ: Sample size to test for interaction between a specific exposure and a second risk factor in a pair-matched case-control study. Stat Med 10(7): 923-935, 2000.

90. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF. The P1A2 polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 105(6): 793-802, 2000.

91. Wang JHC, Goldschmidt-Clermont P, Moldovan N, Yin FCP: Leukotrienes and Tyrosine Phosphorylation Mediate Stretching-Induced Actin Cytoskeletal Remodeling in Endothelial Cells. Cell Motility & Cytoskeleton 46:137-145, 2000.

92. Ozaki M, Deshpande SS, Angkeow P, Bellan J, Lowenstein CJ, Cinauer MC, Goldschmidt-Clermont PJ, Irani K: Inhibition of the rac1 GTPase protects against nonlethal ischemia/reperfusion-induced necrosis and apoptosis in vivo. FASEB J 14(2): 418-429, 2000.

93. Moldovan L, Moldovan NI, Sohn TH, Parikh SA, Goldschmidt-Clermont PJ: Redox changes of cultured endothelial cells and actin dynamics. Circ Res 86(5): 549-557, 2000.

94. Dong C and Goldschmidt-Clermont PJ: Bone sialoprotein and the paradox of angiogenesis versus atherosclerosis (editorial). Circ Res 86:827-828, 2000.

95. Seshiah PN and Goldschmidt-Clermont PJ: Detection of the threatening atherosclerotic plaque: Technological advancement and opportunities (editorial). Am Heart J, 2000.

96. Hassanain H, Sharma YK, Moldovan L, Khramtsov V, Berliner LJ, Duvick JP, Goldschmidt-Clermont PJ. Plant rac proteins induce superoxide in mammalian cells. Biochem Biophys Res Commun 272(3):783-788, 2000.

97. Goldschmidt-Clermont, PJ, Cooke GE, Eaton GM, Binkley PF: PIA2, a variant of GPIIIa implicated in coronary thromboembolic complications. J Am Coll Cardio 36(1): 90-93, 2000.

98. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Start R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J: Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 106(4): 483-491, 2000.

99. Wang JH, Goldschmidt-Clermont P, Yin FC. Contractility affects stress fiber remodeling and reorientation of endothelial cells subjected to cyclic mechanical stretching. Ann Biomed Eng 28(10), 1165-1171, 2000.

100. Moldovan NI, Goldschmidt-Clermont PJ, Parker-Thornburg J, Shapiro SD, Kolattukudy PE. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res 87(5): 378-384, 2000.

101. Boudoulas KD, Cooke GE, Roos CM, Bray PF, Goldschmidt-Clermont PJ. The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 125(1): 112-115, 2001.

102. Dong C, Nevins J, Goldschmidt-Clermont PJ. ABCA1 single nucleotide polymorphisms. Snipping at the pathogenesis of atherosclerosis. Circ Res 88(9): 855-7, 2001.

103. Mikkelsson J, Perola M, Penttila A, Goldschmidt-Clermont PJ, Karhunen PJ. The GPIIIa (beta3 integrin) PlA polymorphism in the early development of coronary atherosclerosis. Atherosclerosis 154(3): 721-727, 2001.

104. Goldschmidt-Clermont PJ, Kandzari DE, Khouri S, Ferrari M. Nanotechnology needs for cardiovascular sciences. Biomed Microdevices 3:2, 83-88, 2001.

105. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé LA, Pfeffer MA, Sacks FM, Braunwald E. The platelet P1(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 88: 347-352, 2001.

106. Kandzari DE, Goldschmidt-Clermont PJ. Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors. J Am Coll Cardiol 38: 1028-1032, 2001.

107. Kovacic HN, Irani, K, Goldschmidt-Clermont PJ. Redox regulation of human RAC1 stability by the proteasome in human aortic endothelial cells. J Biol Chem 276: 45856-45861, 2001.

108. Wang J H-C, Goldschmidt-Clermont P, Wille J, Yin F C-P. Specificity of endothelial cell reorientation in response to cyclic mechanical stretching. J Biomechanics 34: 1563-1572, 2001.

109. de Canniere D, Jansens JL, Goldschmidt-Clermont P, Barvais L, Decroly P, Stoupel E. Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease: Two-year follow-up of new hybrid procedure compared with “on-pump” double bypass grafting. Am Heart J 142(2): 563-570, 2001.

110. Nowicki PT, Flavahan S, Hassanain H, Mitra S, Holland S, Goldschmidt-Clermont PJ, Flavahan NA. Redox signaling of the arteriolar myogenic response. Circ Res 89(2): 114-116, 2001.

111. Su B, Mitra S, Gregg H, Flavahan S, Chotani MA, Clark KR, Goldschmidt-Clermont PJ. Redox regulation of vascular smooth muscle cell differentiation. Circ Res 89(1): 39-46, 2001.

112. Dong C, Goldschmidt-Clermont PJ. Ras activation of NF-kappa B and superoxide. Methods Enzymol 333: 88-96, 2001.

113. Dong C, Zhu S, Alvarez RJ, Goldschmidt-Clermont PJ. Angiotensin II induces PAI-1 expression through MAP kinase-dependent, but TGF beta and PI3 kinase-independent pathway. J Heart Lung Transplant 20(2): 226-227, 2001.

114. Dong C, Zhu S, Yoon W, Wang T, Alvarez RJ, Goldschmidt-Clermont PJ. Upregulation of PA1-1 is mediated through TGF beta/SMAD pathway in transplant arteriopathy. J Heart Lung Transplantation 20(2): 219, 2001.

115. Ozaki M, Deshpande S, Angkeow P, Bellan J, Lowenstein CJ, Dinauer MC, Goldschmidt-Clermont P, Suzuki S, Irani K. Targeted inhibition of the small GTPase protects against ischemia/reperfusion liver injury in mice. Transplant Proc. 2001 Feb-Mar;33(1-2):863-4.

116. Seshiah PN, Kereiakes DJ, Vasudevan SS, Lopes N, Su BY, Flavahan NA, Goldschmidt-Clermont PJ. Activated monocytes induce smooth muscle cell death – Role of macrophage colony-stimulating factor and cell contact. Circulation 105: 174-180, 2002.

117. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, ten Dijke P, White B, Wigley FM, Goldschmidt-Clermont PJ. Deficient Smad7 expression: A putative molecular defect in scleroderma. Proc. Natl Acad. Science 99: 3908-3913, 2002.

118. Lopes N, Vasudevan SS, Alvarez RJ, Binkley PF, Goldschmidt PJ. Pathophysiology of plaque instability: Insights at the genomic level. Prog in Cardiovasc Dis 44: 323-338, 2002.

119. Taylor DA, Hruban R, Rodriquez ER, Goldschmidt-Clermont PJ. Cardiac chimerism as a mechanism for self-repair: Does it happen and if so to what degree? (invited editorial) Circulation 106: 2-4, 2002.

120. Forgione MA, Cap A, Liao R, Moldovan NI, Eberhardt RT, Lim CC, Jones J, Goldschmidt-Clermont PJ, Loscalzo J. Heterozygous cellular glutathione peroxidase deficiency in the mouse: Abnormalities in vascular and cardiac function and structure. Circulation 106: 1154-1158, 2002.

121. Wang T, Dong C, Stevenson SC, Herderich, EE, Marshall-Neff J, Vasudevan SS, Moldovan NI, Michler RE, Movva NR, Goldschmidt-Clermont PJ. Overexpression of Soluble Fas Attenuates Transplant Arteriosclerosis in Rat Aortic Allografts. Circulation 106: 1536-1542, 2002.

122. Dong C, Yoon W, Goldschmidt-Clermont PJ. DNA methylation and atherosclerosis. J Nutr 132: 2406S-2409S, 2002.

123. Goldschmidt-Clermont PJ. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries. J Invasive Cardiology, 14 (Suppl E): 1E-10E, 2002.124. Goldschmidt-Clermont PJ, Kandzari DE, Sketch MH, Phillips HR. Inflammation, platelets and glycoprotein Iib/IIIa inhibitors. J Invasive Cardiology, 14 (Suppl E): 18E-25E, 2002.125. Mayes CE, Kandzari DE, Goldschmidt-Clermont PJ, Phillips HR. The complementary use of glyprotein Iib/llla inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. J Invasive Cardiology, 14 (Suppl E): 36E-46E, 2002.126. Lopes NH, Vasudevan SS, Gregg D, Selvakumar B, Pagano PJ, Kovacic H,, Goldschmidt-Clermont PJ. Rac-dependent monocyte chemoattractant protein-1 production is induced by nutrient deprivation. Circ Res 91(9): 798-805, 2002.127. Dong C, Goldschmidt-Clermont PJ. E2F1: A magic bullet for atherosclerosis? Circulation 106: 2640-2641, 2002.128. Kandzari DE, Goldschmidt-Clermont PJ. Making positive out of negative trials. Am Heart J, 143: 950-951, 2002.129. Lopes N, Gregg D, Vasudevan S, Hassanain H, Goldschmidt-Clermont P, Kovacic H. Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling. Molecular and Cellular Biology, 23: 5401-5408, 2003.130. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA. Aging, vascular progenitor cell exhaustion and atherosclerosis. Circulation, 108: 457-463, 2003.131. Gregg D, Rauscher FM, Goldschmidt-Clermont PJ. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Am J Physiol Cell Physiol 285: C723-C734, 2003.132. Vasudevan SS, Lopes N, Seshiah PN, Wang T, Marsh CB, Kereiakes DJ, Dong C, Goldschmidt-Clermont PJ. Mac-1 and Fas activities are concurrently required for execution of smooth muscle cell death by M-CSF-stimulated macrophages. Cardiovasc Res 59: 723-733, 2003.133. Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray PF. Platelet hyperreactivity in women from families with premature atherosclerosis. J of Am Med Women’s Assoc 58: 272-277, 2003. 134. Goldschmidt-Clermont PJ and Peterson ED. On the memory of a chronic illness. Sci Aging Knowl Environ (SAGE KE) (45), re8, 2003.

135. Goldschmidt-Clermont PJ. Loss of bone marrow-derived vascular progenitor cells leads to inflammation and atherosclerosis. Am Heart J, 146:S5-12, 2003.

136. French JK, Van de Water NS, Sutton TM, Lund M, Gao W, McDowell J, Liu-Stratton Y, Pohorence J, Szymanski D, Goldschmidt-Clermont P, White HD, Browett PJ, Cooke G. Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. Am Heart J, 145(1): 118,124, 2003.

137. Gregg D, Goldschmidt-Clermont PJ. Platelets and cardiovascular disease. Circulation, 108:e88-e90, 2003.

138. Burr D, Doss H, Cooke GE, Goldschmidt-Clermont PJ. A meta-analysis of studies on the association of the platelet P1A polymorphism of glycoprotein IIIa and risk of coronary heart disease. Stat Med, 22(10): 1741-1760, 2003.139. Vijayan KV, Huang TC, Liu Y, Bernardo A, Dong JF, Goldschmidt-Clermont PJ, Alevriadou BR, Bray PF. Shear stress augments the enhanced phenotype of cells expressing the Pro33 isoform of integrin beta3. FEBS Letter, 540(1-3): 41-46, 2003.140. Williams RS and Goldschmidt-Clermont PJ. The genetics of cardiovascular disease: from genotype to phenotype. Dialogues in Cardiovascular Medicine, 9(1): 3-19, 2004.141. Zhu S, Goldschmidt-Clermont PJ, Dong C. Transforming growth factor-beta-induced inhibition of mycogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. Circ Res 94(5):617-625, 2004.142. Goldschmidt-Clermont PJ, Lam G, Dong C. Progenitor cell dysfunction: A key trigger for atherosclerotic inflammation. Drug Discovery Today: Disease Mechanisms, 1:53-58, 2004.143. Califf RM, Ryan T, Douglas P, Goldschmidt-Clermont PJ. A time of accelerated change in academic cardiovascular medicine. J Am Coll Cardiol, 44:1957-1965, 2004.144. Seo D, Wang T, Dressman H, Herderick EE, Iversen ES, Dong C, Vata K, Schulteis R, Milano CA, Rigat F, Pittman J, Nevins JR, West M, Goldschmidt-Clermont PJ. Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol, 24 (10): 1922-1927, 2004.145. Hassanain HH, Irshaid F, Wisel S, Sheridan J, Michler RE, Goldschmidt-Clermont PJ. Smooth muscle cell expression of a constitutive active form of human Rac 1 accelerates cutaneous wound repair. Surgery, 137:92-101, 2005.146. Dai Q, Huang J, Klitzman B, Dong C, Goldschmidt-Clermont PJ, March KL, Rokovich J, Johnstone B, Rebar EJ, Spratt SK, Case CC, Kontos CD, Annex BH. Engineered zinc finger- activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hind-limb ischemia. Circulation 110(16): 2467-2475, 2004.147. Dong C, Crawford LE, Goldschmidt-Clermont PJ. Endothelial progenitor obsolescence and atherosclerotic inflammation. J Am Coll Cardiol, 45:1458-1460, 2005.

148. Ajijola OA, Goldschmidt-Clermont PJ, Satterwhite LL. CD40 ligand: not bad to the bone (marrow) after all. Arterioscler Thromb Vasc Biol, 25(6): 1088-1090, 2005.

149. Karra R, Vemullapalli S, Dong C, Herderick EE, Nevins JR, West M, Goldschmidt-Clermont PJ, Seo D. Molecular evidence for arterial repair in atherosclerosis. Proc Natl Acad Sci. 102 (46):16789-94, Nov, 2005.

150. Goldschmidt-Clermont PJ, Creager MA, Losordo DW, Lam GK, Wassef M, Dzau VJ.Atherosclerosis 2005: Recent discoveries and novel hypotheses. Circulation. 112(21):3348-53, Nov, 2005.

151. Kong DF, Goldschmidt-Clermont PJ. Tiny solutions for giant cardiac problems. Trends in Cardiovasc Med. 15(6):207-11, Aug, 2005.

152. Zhu S, Goldschmidt-Clermont PJ, Dong C. Inactivation of monocarboxylate transporter MCT3 by DNA methylation in atherosclerosis. Circulation. 112 (9): 1353-61, Aug, 2005.

153. Liu X, Zhu S, Wang T, Hummers L, Wigley F, Goldschmidt-Clermont PJ, Dong C. Paclitaxel modulates TGF. Signaling in scleroderma skin grafts in immunodeficient mice. Plos Med. 2(12): e354, Dec, 2005.

154. Wang T, Davis BH, Herderick EH, Whitesides JF, Yue B, Taylor DA, Goldschmidt-Clermont PJ., Transfer of bone marrow cells suppresses atherosclerotic inflammation in aged ApoE-deficient mice. Circulation. In press, 2005.

155. Goldschmidt-Clermont PJ, Diehl AM. Arterial homeostasis, inflammation, and erythropoietic growth factors. Rev Cardiovasc Med. 2005;6 Suppl 3:S22-6.

156. Kravchenko J, Goldschmidt-Clermont PJ, Powell T, Stallard E, Akushevich I, Cuffe MS, Manton KG. Endothelial progenitor cell therapy for atherosclerosis: The philosopher’s stone for an aging population? Sci Aging Knowledge Environ, 25:18, 2005

157. Stenger JE, Xu H, Haynes C, Hauser ER, Pericak-Vance M, Goldschmidt-Clermont PJ, Vance JM. Statistical viewer: a tool to upload and integrate linkage and association data as plots displayed within the Ensembl genome browser. BMC Bioinformatics 12(6), 95, 2005.

158. Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, Bray PF, Binkley PF, Goldschmidt-Clermont PJ. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol. 2006 Feb 7;47(3):541-6. Epub 2006 Jan 18.

159. Niu J, Azfer A, Deucher MF, Goldschmidt-Clermont PJ, Kolattukudy PE. Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specific expression of MCP-1. J Mol Cell Cardiol. 2006 Jun;40(6):810-20. Epub 2006 May 5.

160. Moldovan L, Mythreye K, Goldschmidt-Clermont PJ, Satterwhite LL. Reactive oxygen species in vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. Cardiovasc Res. 2006 Jul 15;71(2):236-46. Epub 2006 May 9.

161. Boudoulas KD, Montague KR, Goldschmidt-Clermont PJ, Cooke GE. Estradiol increases platelet aggregation in PlA1/A1 individuals. Am Heart J. 2006 Jul;152(1):136-9.

162. Seo D, Ginsburg GS, Goldschmidt-Clermont PJ. Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. J Am Coll Cardiol. 2006 Jul 18;48(2):227-35.

163. Kunz GA, Liang G, Cuculoski F, Gregg D, Vata KC, Shaw LK, Goldschmidt-Clermont PJ, Dong C, Taylor DA, Peterson ED. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J. 2006 Jul;152(1):190-5.

164. Connelly JJ, Wang T, Cox JE, Haynes C, Wang L, Shah SH, Crosslin DR, Hale AB, Nelson S, Crossman DC, Granger CB, Haines JL, Jones CJ, Vance JM, Goldschmidt-Clermont PJ, Kraus WE, Hauser ER, Gregory SG.GATA2 Is Associated with Familial Early-Onset Coronary Artery Disease.. PLoS Genet. 2006 Aug 25;2(8).

165. Montague CR, Hunger MG, Gavrilin MA, Phillips GS, Goldschmidt-Clermont PJ, Marsh, CB. Activation of Estrogen Receptor Alpha Reduces Aortic Smooth Muscle Differentiation. Circ Res. 2006 Sep 1;99(5):477-84.

166. Donahue MP, Rose K, Hochstrasser D, Vonderscher J, Grass P, Chibout SD, Nelson CL, Sinnaeve P, Goldschmidt-Clermont PJ, Granger CB. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. Am Heart J. 2006 Sep;152 (3):478-85.

167. Kim J, Kim JY, Song KY, Lee YH, Seo JS, Jelinek J, Goldschmidt-Clermont PJ, Issa, JP. Epigenetic changes in estrogen receptor gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta. 2006 Oct 12.

168. Cooke G, Goldschmidt-Clermont PJ. The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opin. Drug Saf. 2006 Nov;5(6):815-26.

169. Choi SS, Sicklick JK, Ma Q, Yang L, Huang J, Qi Y, Chen W, Li YX, Goldschmidt-Clermont PJ, Diehl AM. Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. Hepatology. 2006 Nov;44(5):1267-77.

170. Zhu S, Liu X, Li Y, Goldschmidt-Clermont PJ, Dong C. Aging in the Atherosclerosis Milieu May Accelerate the Consumption of Bone Marrow Endothelial Progenitor Cells. Arteriosclerosis, Thrombosis, and Vascular Biology (published online Nov 9, 2006).

171. Hassanain HH, Gregg D, Marcelo ML, Zweier JL, Souza HP, Selvakumar B, Ma Q, Moustafa-Bayoumi M, Binkley PF, Flavahan NA, Morris M, Dong C, Goldschmidt-Clermont PJ. Hypertension Caused by Transgenic Over-expression of Rac1. Antioxidants & Redox Signaling 2007 Jan;9(1):91-100.

172. Seo DM, Goldschmidt-Clermont PJ. Unraveling the genetics of atherosclerosis: implications for diagnosis and treatment. Expert Rev Mol Diagn. 2007 Jan;7(1):45-51.

173. Vemulapalli S, Metzler SD, Akabani G, Petry NA, Niehaus NJ, Liu X, Patil NH, Greer KL, Jaszczak RJ, Coleman RE, Dong C, Goldschmidt-Clermont PJ, Chin BB. Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT. Radiology. 2007 Jan;242(1):198-207.

174. Wang L, Vance J, Pericak-Vance M, Shah S, Hauser ER, Goldschmidt-Clermont PJ, Krauss WE. Peak-wide mapping on chromosome 3q13 identifies the kalirin gene as a novel susceptibility gene for coronary artery disease. American Journal of Human Genetics. 2007 Apr;80(4):650-63. Epub 2007 Feb 8.

175. Dong, C. and Goldschmidt-Clermont PJ. Endothelial progenitor cells: A promising therapeutic alternative for cardiovascular disease. J Interv Cardiol. 2007 Apr;20(2):93-9.

176. Seo DM, Goldschmidt-Clermont PJ, West M. Of Mice and Men: Sparse Statistical Modeling in Cardiovascular Genomics. Annals of Applied Statistics. 2007, Vol. 1, No. 1, 152-178.

177. Tabatabaei N, Stout J, Goldschmidt-Clermont P, Murdoch D. Central Nervous System Infection and Cutaneous Lymphadenitis Due to Mycobacterium kansasii in an Immunocompetent Patient. Infection. 2007 Aug; 35(4):291-4. Epub 2007 Jul 23.

178. Liao SM, Goldschmidt- Clermont PJ, Sugarman J. Ethical and policy issues relating to progenitor-cell-based strategies for prevention of atherosclerosis. J Med Ethics. 2007 Nov; 33(11):643-6.

179. Povsic TJ, Zavodni KL, Kelly FL, Zhu S, Goldschmidt-Clermont PJ, Dong C, Peterson ED. Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity. J Am Coll Cardiol. 2007 Dec 4; 50(23):2243-8. Epub 2007 Nov 19.

180. Moustafa-Bayoumi M, Alhaj MA, El-Sayed O, Wisel S, Chotani MA, Aboelnaga ZA, Hassona MD, Morris M, Nuovo G, Zweier JL, Goldschmidt-Clermont P, Hassanain H. Vascular hypertrophy and hypertension caused by transgenic overexpression of profilin 1. J Biol Chem. 2007; 282(52):37632-37639.

181. Shah SH, Hauser ER, Crosslin D, Wang L, Haynes C, Connelly J, Nelson S, Johnson J, Gadson S, Nelson CL, Seo D, Gregory S, Kraus WE, Granger CB, Goldschmidt-Clermont P, Newby LK. ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention. Atherosclerosis. 2008 Feb 12; [Epub ahead of print]

182. Wang H, Yan B, Satterwhite LL, Ma Q, Goldschmidt-Clermont PJ. Increased activity of phosphatase PP2A in the presence of the PlA2 polymorphism of alphaIIbbeta3. Biochem Biophys Res Commun. Volume 367, Issue 1, 29 February 2008, Pages 72-77. Epub 2007 Dec 26. 183. Sutton BS, Crosslin DR, Shah SH, Nelson SC, Bassil A, Hale AB, Haynes C, Goldschmidt-Clermont PJ, Vance JM, Seo D, Kraus WE, Gregory SG, Hauser ER. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum Mol Genet. 2008; 17 (9): 1318-28. Epub 2008 Jan 18.

184. Selvakumar B, Hess D, Goldschmidt-Clermont PJ, Stamler J. Co – regulation of constitutive nitric oxide synthases and NADPH oxidase by the small GTPase Rac. FEBS Lett. 582 (2008) 2195-2202. Epub 2008 May 22.

185. Wang L, Hauser B, Shah S, Seo D, Sivashanmugam P, Exum S, Gregory S, Haines J, Crossman D, Haynes C, Kraus W, Freedman N, Pericak-Vance M, Goldschmidt-Clermont PJ, Vance J. Polymorphisms of the tumor suppressor gene LSAMP are associated with left main coronary artery disease. Annals of Human Genetics 2008 Jul; 72 (Pt 4): 443-53. Epub 2008 Jul 3.

186. Povsic T. and Goldschmidt-Clermont PJ. Review: Endothelial progenitor cells: markers of vascular reparative capacity. Therapeutic Advances in Cardiovascular Disease 2008; 2; 199-213.

187. Ajijola OA, Dong C, Herderick EE, Ma Q, Goldschmidt-Clermont PJ, Yan Z. Voluntary Running Suppresses Proinflammatory Cytokines and Bone Marrow Endothelial Progenitor Cell Levels in Apolipoprotein-E-Deficient Mice. Antioxidants & Redox Signaling 2009; 11 (1).

188. Goldschmidt-Clermont PJ, Dong C, West M, Seo D. Of Cardiovascular Illness and Diversity of Biological Response. Trends in Cardiovascular Medicine 2008; 18 (5) 194-197.